Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30137686 | 1.00 | RAB9A (0.45) | RAB9ALRRK2LMNAHTTCYP11B1 | |
| SCHEMBL2259993 | 0.91 | LRRK2 (0.37) | RAB9ALRRK2LMNAHTTMAPT | |
| SCHEMBL83685 | 0.89 | MAPT (0.46) | LMNAMAPTALDH1A1POLBKDM4E | |
| SCHEMBL19328940 | 0.89 | CSNK2A2 (0.37) | RAB9ALRRK2ALDH1A1KDM4EMEN1 | |
| SCHEMBL1301071 | 0.88 | MAPT (0.38) | MAPTALDH1A1POLBKDM4EGAA | |
| SCHEMBL6730444 | 0.88 | MAPT (0.39) | MAPTALDH1A1POLBKDM4EGAA | |
| SCHEMBL1497638 | 0.88 | MAPT (0.39) | MAPTALDH1A1POLBKDM4EGAA | |
| SCHEMBL1658265 | 0.87 | MAPT (0.38) | MAPTALDH1A1POLBKDM4EGAA | |
| SCHEMBL12064247 | 0.87 | MAPT (0.38) | MAPTALDH1A1POLBKDM4EGAA | |
| SCHEMBL3677899 | 0.87 | GAA (0.41) | LMNAMAPTALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115724847-A | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives | 拜耳知识产权有限责任公司 | 2023-03-03 | — | — | CN | disclosed |
| CN-101631464-B | 2,3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives for the treatment of hyperproliferative diseases and angiogenesis-related diseases | 拜耳知识产权有限责任公司 | 2022-12-06 | — | — | CN | disclosed |
| EP-2638045-B1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER IP GMBH (DE) | 2022-08-31 | — | — | EP | disclosed |
| EP-2638045-B1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER IP GMBH (DE) | 2022-08-31 | — | — | EP | disclosed |
| CN-108774232-B | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives | 拜耳知识产权有限责任公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-105254634-B | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives useful in the treatment of hyperproliferative diseases and angiogenesis-related diseases | 拜耳知识产权有限责任公司 | 2022-05-27 | — | — | CN | disclosed |
| US-RE46856-E1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| US-RE46856-E1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| US-RE46856-E1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| US-9902727-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-8466283-B2 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20110190281-A1 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190281-A1 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190281-A1 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-14 | — | — | US | disclosed |
| EP-2096919-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009091550-A2 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2008070150-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070150-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190281-A1 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | PIK3CA, PIK3CD, PIK3CB | RAB9A 901/4885LRRK2 1422/4885LMNA 3962/4885 |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | PIK3CA, PIK3CD, PIK3CB | RAB9A 660/4885LRRK2 985/4885LMNA 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.